1
|
Kwon HY, Kim J, Ahn SJ. Screening practices and risk assessment for maculopathy in pentosan polysulfate users across different exposure levels. Sci Rep 2024; 14:11270. [PMID: 38760453 PMCID: PMC11101426 DOI: 10.1038/s41598-024-62041-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 05/13/2024] [Indexed: 05/19/2024] Open
Abstract
In this population-based cohort study, we investigated screening practices for maculopathy and incidences of specific macular/retinal conditions in pentosan polysulfate (PPS) users and assessed the relationship between these outcomes and drug exposure levels. Using a health claims database that covers approximately 50 million Koreans, we identified 138,593 individuals who were prescribed PPS between 2010 and 2021. For the 133,762 PPS users who initiated therapy between 2012 and 2021, the cumulative PPS dose for each participant was evaluated, and based on their cumulative PPS dose, patients were categorized into the high-risk (≥ 500 g), low-risk (50-500 g), and minimal exposure (< 50 g) groups. We analyzed the performance and methods of these examination methods used between 2018 and 2021 and compared them among cumulative dose groups to determine whether high-risk users underwent maculopathy screening more frequently or appropriately. We assessed the cumulative incidence of overall macular degeneration and maculopathy excluding common macular diseases following PPS therapy initiation. Most PPS users (99.7%) received a cumulative PPS dose < 500 g and the high- and low-risk groups comprised 445 (0.3%) and 22,185 (16.6%) patients, respectively. During the study period, monitoring examinations were conducted in 52.6% and 49.4% of high- and low-risk patients, respectively, revealing no significant difference between the two groups (P = 0.156). No significant differences were observed in the annual percentages of patients receiving ophthalmic examinations between the high- and low-risk groups (all P > 0.05). The cumulative incidences of overall macular degeneration and maculopathy excluding common macular diseases in high-risk users were 19.3% and 9.0%, respectively, which were significantly different from those of low-risk users (both P < 0.001). Multivariate Cox regression analysis revealed significantly higher risks of maculopathy excluding common macular diseases in the low- (Hazard ratio [HR] of 1.55 [95% CI 1.13-2.12]) and high-risk groups (HR of 1.66 [95% CI 1.22-2.27]) compared to the minimal exposure group. Our findings suggest a need for increased emphasis on PPS maculopathy screening in high-risk patients, highlighting raising awareness regarding exposure-dependent risks and the establishment of screening guidelines.
Collapse
Affiliation(s)
- Hyeon Yoon Kwon
- Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, 222-1 Wangsipli-Ro, Seongdong-Gu, Seoul, 04763, Republic of Korea
| | - Jiyeong Kim
- Department of Pre-Medicine, College of Medicine, and Biostatistics Lab, Medical Research Collaborating Center (MRCC), Hanyang University, Seoul, Republic of Korea
| | - Seong Joon Ahn
- Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, 222-1 Wangsipli-Ro, Seongdong-Gu, Seoul, 04763, Republic of Korea.
- Department of Pre-Medicine, College of Medicine, and Biostatistics Lab, Medical Research Collaborating Center (MRCC), Hanyang University, Seoul, Republic of Korea.
| |
Collapse
|
2
|
Hom GL, Kuo BL, Ross JH, Chapman GC, Sharma N, Sastry R, Muste JC, Greenlee TE, Conti TF, Singh RP, Sharma S. Characterization of pentosan polysulfate patients for development of an alert and screening system for ophthalmic monitoring. CANADIAN JOURNAL OF OPHTHALMOLOGY 2024; 59:128-136. [PMID: 36878265 DOI: 10.1016/j.jcjo.2023.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 12/27/2022] [Accepted: 01/30/2023] [Indexed: 03/06/2023]
Abstract
OBJECTIVE Pentosan polysulfate (PPS; ELMIRON, Janssen Pharmaceuticals, Titusville, NJ) is a U.S. Food and Drug Administration-approved oral medication for interstitial cystitis. Numerous reports have been published detailing retinal toxicity with the use of PPS. Studies characterizing this condition are primarily retrospective, and consequently, alert and screening systems need to be developed to actively screen for this disease. The goal of this study was to characterize ophthalmic monitoring trends of a PPS-using patient sample to construct an alert and screening system for monitoring this condition. METHODS A single-institution retrospective chart review was conducted between January 2005 and November 2020 to characterize PPS use. An electronic medical record (EMR) alert was constructed to trigger based on new PPS prescriptions and renewals offering ophthalmology referral. RESULTS A total of 1407 PPS users over 15 years was available for characterization, with 1220 (86.7%) being female, the average duration of exposure being 71.2 ± 62.6 months, and the average medication cumulative exposure being 669.7 ± 569.2 g. A total of 151 patients (10.7%) had a recorded visit with an ophthalmologist, with 71 patients (5.0%) having optical coherence tomography imaging. The EMR alert fired for 88 patients over 1 year, with 34 patients (38.6%) either already being screened by an ophthalmologist or having been referred for screening. CONCLUSIONS An EMR support tool can improve referral rates of PPS maculopathy screening with an ophthalmologist and may serve as an efficient method for longitudinal screening of this condition with the added benefit of informing pentosan polysulfate prescribers about this condition. Effective screening and detection may help determine which patients are at high risk for this condition.
Collapse
Affiliation(s)
- Grant L Hom
- Case Western Reserve University School of Medicine, Cleveland, OH
| | - Blanche L Kuo
- Case Western Reserve University School of Medicine, Cleveland, OH
| | - James H Ross
- Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, Ohio
| | - Graham C Chapman
- Department of Obstetrics and Gynecology, Women's Health Institute, Cleveland Clinic, Cleveland, Ohio
| | - Neha Sharma
- Case Western Reserve University School of Medicine, Cleveland, OH
| | - Resya Sastry
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
| | - Justin C Muste
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
| | - Tyler E Greenlee
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
| | - Thais F Conti
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
| | - Rishi P Singh
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH
| | - Sumit Sharma
- Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH.
| |
Collapse
|
3
|
Fogel Levin M, Santina A, Corradetti G, Au A, Lu A, Abraham N, Somisetty S, Romero Morales V, Wong A, Sadda S, Sarraf D. Pentosan Polysulfate Sodium-Associated Maculopathy: Early Detection Using OCT Angiography and Choriocapillaris Flow Deficit Analysis. Am J Ophthalmol 2022; 244:38-47. [PMID: 35901995 DOI: 10.1016/j.ajo.2022.07.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Revised: 07/18/2022] [Accepted: 07/18/2022] [Indexed: 01/30/2023]
Abstract
PURPOSE To compare choriocapillaris flow deficit (CC-FD) analysis using optical coherence tomography angiography (OCTA) in eyes of patients treated with high cumulative dosages of pentosan polysulfate sodium (PPS) but no signs of retinal toxicity versus healthy age-matched controls. DESIGN Retrospective clinical cohort study. METHODS Patients treated with PPS for interstitial cystitis with a cumulative dose of > 1000 g underwent multimodal imaging screening to exclude evidence of PPS maculopathy or other retinal findings. All study patients and age-matched healthy controls completed a 3 × 3 mm macular volume scan OCTA using the SOLIX full-range OCT. En face OCTA images at the level of the CC were exported and CC-FDs were computed and compared between groups. RESULTS Fifteen patients treated with PPS and 15 age-matched controls were included. The mean PPS cumulative dose was 1974 ± 666 g over a mean of 17.6 ± 6.8 treatment years. All patients registered a visual acuity of 20/25 or better and normal fundus autofluorescence (FAF), OCT, multicolor, near-infrared reflectance (NIR), and ultra-widefield fundus color and autofluorescence images. The CC-FD was 32.7 ± 3.6% in the PPS group compared with 28.6 ± 4.3% in the control group (P = .023). CONCLUSIONS Patients treated with PPS long enough to accumulate dosages > 1000 g showed significant CC flow impairment before the development of macular toxicity signs with OCT, NIR, and FAF compared with age-matched normal controls. Thus, the choroid may be the earliest manifestation of ocular toxicity, predating the development of clinically evident retinal pigment epithelium (RPE) injury. The subsequent RPE disruption may be the result of choriocapillaris impairment or primary PPS toxicity. Assessment of the CC on OCTA may be a useful tool for early detection of toxicity, although further longitudinal studies are required.
Collapse
Affiliation(s)
- Meira Fogel Levin
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Ahmad Santina
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Giulia Corradetti
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S); Doheny Eye Institute, Los Angeles, California, USA (G.C, S.V.S)
| | - Adrian Au
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Anthony Lu
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Neda Abraham
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Swathi Somisetty
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Veronica Romero Morales
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - Alice Wong
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S)
| | - SriniVas Sadda
- Doheny Eye Institute, Los Angeles, California, USA (G.C, S.V.S); Department of Ophthalmology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA (S.V.S)
| | - David Sarraf
- Stein Eye Institute, University of California-Los Angeles School of Medicine, Los Angeles, USA (M.F.L, A.S, G.C, A.A, A.L, N.A, S.S, V.R.M, A.W, D.S); Greater Los Angeles VA Healthcare Center, Los Angeles, California, USA (D.S).
| |
Collapse
|